1.	Phase III Randomized Study of Caspofungin Acetate Versus Fluconazole to Prevent Invasive Fungal Infections in Pediatric and Adult Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care Status: Active Age: 3 months to 30 years Sponsor: NCI Protocol IDs: COG-ACCL0933, NCT01307579
2.	Phase III Randomized Study of Caspofungin Acetate Versus Fluconazole or Voriconazole Prophylaxis in Patients at High-Risk for Invasive Fungal Infections Following Allogeneic Hematopoietic Stem Cell Transplantation Phase: Phase III Type: Supportive care, Treatment Status: Approved-not yet active Age: 3 months to 20 years Sponsor: NCI Protocol IDs: COG-ACCL1131, ACCL1131, NCT01503515
3.	Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection Phase: Phase II Type: Supportive care Status: Active Age: 18 to 55 Sponsor: Other Protocol IDs: RJH-2011-71, NCT01501708